{
    "paper_id": "ee08f571d5b32d1636159134fc3049a1b9792a45",
    "metadata": {
        "title": "Title: Clinical characteristics associated with COVID-19 severity in California",
        "authors": [
            {
                "first": "Samuel",
                "middle": [
                    "J S"
                ],
                "last": "Rubin",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Stanford University School of Medicine",
                    "location": {
                        "settlement": "Stanford",
                        "region": "CA",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "+",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Stanford University School of Medicine",
                    "location": {
                        "settlement": "Stanford",
                        "region": "CA",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Samuel",
                "middle": [
                    "R"
                ],
                "last": "Falkson",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Stanford University School of Medicine",
                    "location": {
                        "settlement": "Stanford",
                        "region": "CA",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Ba",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Stanford University School of Medicine",
                    "location": {
                        "settlement": "Stanford",
                        "region": "CA",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Nicholas",
                "middle": [],
                "last": "Degner",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Stanford University School of Medicine",
                    "location": {
                        "settlement": "Stanford",
                        "region": "CA",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Catherine",
                "middle": [],
                "last": "Blish",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Stanford University School of Medicine",
                    "location": {
                        "settlement": "Stanford",
                        "region": "CA",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "Chan-Zuckerberg",
                "middle": [],
                "last": "Rubin",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Stanford University School of Medicine",
                    "location": {
                        "settlement": "Stanford",
                        "region": "CA",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "San",
                "middle": [],
                "last": "Biohub",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Stanford University School of Medicine",
                    "location": {
                        "settlement": "Stanford",
                        "region": "CA",
                        "country": "USA"
                    }
                },
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Francisco",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Stanford University School of Medicine",
                    "location": {
                        "settlement": "Stanford",
                        "region": "CA",
                        "country": "USA"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a global threat. Disease severity varies widely from mild (81%), requiring hospitalization (12%), to death (1.8-3.4% ) (1) .",
            "cite_spans": [
                {
                    "start": 245,
                    "end": 248,
                    "text": "(1)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "Introduction:"
        },
        {
            "text": "The growing number of US COVID-19 cases is expected to tax the capacity of health care delivery systems. Analysis of clinical characteristics at time of patient presentation associated with disease severity is immediately useful. Recognizing the rapid utility of such data, we evaluated clinical characteristics and disease course of patients with confirmed COVID-19 at Stanford Hospital.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Introduction:"
        },
        {
            "text": "With approval of the Stanford Institutional Review Board, patient charts were analyzed if they were diagnosed with COVID-19 by RT-PCR, received care at Stanford Hospital by March 16, 2020, and had past medical history documentation. Statistical analyses were conducted in Microsoft Excel and R.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Methods:"
        },
        {
            "text": "Of 54 patients analyzed, the median age was 53.5 years (IQR, 32.75; range, 20-91), 53.7% (29) were male, 18 were inpatients, and 36 were outpatients (Table 1) . Based on chart documentation of past medical history, 14 had hypertension, 13 had hyperlipidemia, and 7 had diabetes (6 type 2, 1 type 1).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 149,
                    "end": 158,
                    "text": "(Table 1)",
                    "ref_id": null
                }
            ],
            "section": "Results:"
        },
        {
            "text": "Consistent with previous COVID-19 reports, the most common prediagnosis comorbidity in 24 patients (25.9%) was hypertension; this rate does not significantly differ from the US . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Results:"
        },
        {
            "text": "is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.27.20043661 doi: medRxiv preprint prevalence (Fisher's exact test, p = 0.671) (2, 3) . Angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) use in 9 patients (16.7%) was also not significantly different from the US prevalence (Fisher's exact test, p = 1.000) (4).",
            "cite_spans": [
                {
                    "start": 188,
                    "end": 191,
                    "text": "(2,",
                    "ref_id": null
                },
                {
                    "start": 192,
                    "end": 194,
                    "text": "3)",
                    "ref_id": "BIBREF4"
                }
            ],
            "ref_spans": [],
            "section": "Results:"
        },
        {
            "text": "In univariate analysis, age, lower oxygen saturation at initial examination, and hypertension were significantly associated with recommendation for further hospital care, lower oxygen saturation was associated with admission to ICU, age and lower oxygen saturation were associated with diagnosis of pneumonia, and lower oxygen saturation and hypertension were associcated with progression to acute respiratory distress syndrome (ARDS) ( Table 2 ). Use of ACE-I or ARB was not significantly associated with recommendation for further hospital care, admission to ICU, diagnosis of pneumonia, or progression to ARDS. When analyzed by logistic regression to control for age, the only factor independently significantly associated with recommendation for further in-hosptial care, diagnosis of pneumonia, and progression to ARDS was initial oxygen saturation measurement as a continuous variable.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 437,
                    "end": 444,
                    "text": "Table 2",
                    "ref_id": "TABREF1"
                }
            ],
            "section": "Results:"
        },
        {
            "text": "Clinical characteristics of US COVID-19 patients and factors from initial presentation that associate with disease severity were identified. Lower oxygen saturation at presentation was independently significantly associated with measures of disease severity, and thus may serve as a useful indicator of potential disease progression. Additionally, history of hypertension predisposed patients to worse outcomes such as ARDS, although not independently of age, consistent with previous reports (2).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion:"
        },
        {
            "text": "Several factors, including age-related changes in the immune system and other physiological processes could contribute to COVID-19 disease severity. While hypertension is associated with . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion:"
        },
        {
            "text": "is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.27.20043661 doi: medRxiv preprint COVID-19 morbidity, it is not independent of age; thus further study is needed to elucidate the extent to which hypertension and/or dysregulation of the renin-angiotensin-aldosterone system (RAAS) contributes to COVID-19 pathogenesis. The idea that RAAS dysregulation may influence disease progression warrants further exploration into the usefulness of ACE-I and/or ARB therapies in COVID-19 management.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion:"
        },
        {
            "text": "The potential role of the RAAS system in COVID-19 pathogenesis stems from mounting sequence and structural evidence indicating entry of SARS-CoV-2 via interaction of its spike protein with its human host receptor angiotensin-converting enzyme 2 (ACE2) (5). It is difficult to predict the effects of RAAS blockade in treatment of COVID-19, as it may increase expression of ACE2, with known anti-inflammatory and pulmonary protective properties, yet simultaneously promote viral entry (6). However, RAAS blockade may also increase soluble ACE2, which could serve as a decoy receptor protecting against viral entry.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion:"
        },
        {
            "text": "In our study, history of ACE-I or ARB use did not affect diagnosis rate or predispose patients to worse disease outcomes. However, our study is underpowered to draw definitive conclusions from such negative data. We hope these initial findings motivate larger studies intended to characterize RAAS blockade in the COVID-19 setting.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion:"
        },
        {
            "text": "Limitations of this study include lack of some data on disease progression due to retrospective design and potential selection bias of patients with severe disease more likely to have SARS-CoV-2 testing and extensive charting. However, this US data is immediately clinically relevant given the rapidly evolving pandemic and will help clinicians identify and treat patients most at risk of severe disease.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion:"
        },
        {
            "text": ". CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion:"
        },
        {
            "text": "is the (which was not peer-reviewed) The copyright holder for this preprint . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion:"
        },
        {
            "text": "is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.27.20043661 doi: medRxiv preprint",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Discussion:"
        }
    ],
    "bib_entries": {
        "BIBREF1": {
            "ref_id": "b1",
            "title": "COVID-19) -United States",
            "authors": [],
            "year": 2019,
            "venue": "Severe Outcomes Among Patients with Coronavirus Disease",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.15585/mmwr.mm6912e2"
                ]
            }
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "Zheng",
                    "middle": [
                        "J"
                    ],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "JAMA Intern Med",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1001/jamainternmed.2020.0994"
                ]
            }
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Hypertension Prevalence and Control Among Adults: United States",
            "authors": [],
            "year": 2016,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "MD, MPH of Stanford University School of Medicine, USA, and Andrew Michael South, MD, MS of Wake Forest School of Medicine, USA for helpful discussions. No compensation was received for their roles in the study.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JHY, Alger HM, Wong SS, Muntner P. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation 2018. doi:10.1161/CIR.0000000000000558 author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol. 2020. 6. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation 2005. doi:10.1161/CIRCULATIONAHA.104.510461author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Table 1. Clinical characteristics of 54 patients with COVID-19 in California total patient number in category n, patients in category with data available SD, standard deviation bold, statistically significant . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.03.27.20043661 doi: medRxiv preprint",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "Correlates of clinical progression Use of angiotensin converting enzyme inhibitors (ACE-I) \u2020 0.289 0.994 Use of angiotensin II receptor blockers (ARB) \u2020 Use of angiotensin converting enzyme inhibitors (ACE-I) \u2020 1.000 0.997 Use of angiotensin II receptor blockers (ARB) \u2020 0.330 0.467 * Two-tailed homoscedastic Student's T test for univariate analysis \u2020 Fisher's exact test for univariate analysis bold, statistically significant",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "We thank Arjun Rustagi, MD, PhD, Vivek Bhalla, MD, and Glenn",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Acknowledgements:"
        }
    ]
}